PNPLA3 as a liver steatosis risk factor following living‐donor liver transplantation for hepatitis C

E-ISSN： 1872-034x|48|3|E335-E339

ISSN： 1386-6346

Source： HEPATOLOGY RESEARCH, Vol.48, Iss.3, 2018-02, pp. : E335-E339

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The common I148 M variant of PNPLA3 does not predict fibrosis progression after liver transplantation for hepatitis C

HEPATOLOGY, Vol. 54, Iss. 4, 2011-10 ,pp. : 1483-1484

John Wiley & Sons Inc

Access to resources Recommend Favorite

Hepatocellular Carcinoma in Patients Undergoing Living-Donor Liver Transplantation

Intervirology, Vol. 51, Iss. 1, 2008-06 ,pp. : 46-51

Karger

Access to resources Recommend Favorite

Risk factors for hepatitis B virus recurrence after living donor liver transplantation: A 17‐year experience at a single center

HEPATOLOGY RESEARCH, Vol. 45, Iss. 12, 2015-12 ,pp. : 1203-1210

John Wiley & Sons Inc

Access to resources Recommend Favorite

Outcomes of living donor liver transplantation for hepatitis C virus‐positive recipients in Japan: results of a nationwide survey

TRANSPLANT INTERNATIONAL (ELECTRONIC), Vol. 27, Iss. 8, 2014-08 ,pp. : 767-774

John Wiley & Sons Inc

Access to resources Recommend Favorite

Steroid minimization immunosuppression protocol using basiliximab in adult living donor liver transplantation for hepatitis C virus‐related cirrhosis

HEPATOLOGY RESEARCH, Vol. 45, Iss. 12, 2015-12 ,pp. : 1178-1184

John Wiley & Sons Inc

Access to resources Recommend Favorite